Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Call for patients to have more choice over diabetes treatment

  • 1 Comment

Patients should be “at the heart” of clinical decisions on type 2 diabetes treatment, according to “pragmatic” new international guidance on diabetes.

The joint guideline was published yesterday by the European Association for the Study of Diabetes and the American Diabetes Association. It was launched at this year’s annual EASD meeting in Berlin.

The document is less prescriptive than previous guidance of its type, and advocates more patient involvement in choice of therapy and the setting of treatment goals.

The EASD and ADA said patient-centred care should be the “organising principal underlying” the treatment of long-term conditions.

EASD president Andrew Boulton, professor of medicine at Manchester University, added: “Given the uncertainties in terms of type and sequence of therapies, this approach is particularly appropriate in type 2 diabetes.”

It highlights that diet and exercise remain the foundation of treatment and metformin is the optimal first-line drug. But after metformin, there are limited data to guide treatment, it says.

The guideline highlights that “ultimately” patients make the final decisions on their lifestyle choices and, to some degree, the drug interventions they use.

Equally, the new guidance also calls for individualised goals. While general recommendations regarding glycaemic control focused in the past on an HbA1c target below 7%, the new guidance calls for a more “pragmatic viewpoint”.

It says the precise glycaemic target should take into account individual patient factors, including their attitude and expected treatment efforts, disease duration, life expectancy and other co-morbidities.

Professor Boulton said: “The overarching goal should be to reduce blood glucose concentrations safely to a range that will substantially minimise long-term complications, but, always keeping in mind the potential adversities with treatment burden, particularly in the elderly who are more often exposed to multiple drug treatments.”

The guidance is published online in the journal Diabetologia.

  • 1 Comment

Readers' comments (1)

  • Is this a polite way of telling non complaint patients to treat themselves ! ?

    Unsuitable or offensive? Report this comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs